 SAN DIEGO, March 11, 2021 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced that Dr. Mark Erlander, chief executive officer of Cardiff Oncology, will present and participate in one-on-one investor meetings at the Oppenheimer 31st Annual Healthcare Conference taking place March 16-18, 2021. Presentation details can be found below. 